Stryker Total Cost of Revenue decreased by 13.1% to $2.21B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.1%, from $2.12B to $2.21B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 10.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.52B | $1.52B | $1.66B | $1.54B | $1.67B | $1.70B | $1.97B | $1.76B | $1.82B | $1.75B | $2.11B | $1.91B | $2.01B | $1.98B | $2.26B | $2.12B | $2.18B | $2.21B | $2.54B | $2.21B |
| QoQ Change | — | -0.3% | +9.1% | -6.9% | +8.2% | +1.8% | +15.9% | -10.4% | +3.0% | -3.5% | +20.6% | -9.6% | +5.0% | -1.4% | +14.4% | -6.2% | +2.8% | +1.1% | +15.3% | -13.1% |
| YoY Change | — | — | — | — | +9.5% | +11.8% | +18.7% | +14.3% | +8.9% | +3.2% | +7.4% | +8.4% | +10.5% | +12.9% | +7.1% | +11.1% | +8.7% | +11.5% | +12.4% | +4.1% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| MedSurg and Neurotechnology: | $1.18B | $1.41B | $1.43B | $1.70B | $1.29B |
| Orthopaedics | $775.00M | — | — | — | — |
| Total | $2.12B | $2.18B | $2.21B | $2.54B | $2.21B |